GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Cyclically Adjusted PS Ratio

Diamyd Medical AB (OSTO:DMYD B) Cyclically Adjusted PS Ratio : (As of Jul. 05, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Diamyd Medical AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cyclically Adjusted PS Ratio Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.66 1,742.96 741.86 489.50 -

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 575.71 - - 517.52 -

Competitive Comparison of Diamyd Medical AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted PS Ratio falls into.


;
;

Diamyd Medical AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Diamyd Medical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2025 is calculated as:

For example, Diamyd Medical AB's adjusted Revenue per Share data for the three months ended in May. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of May. 2025 (Change)*Current CPI (May. 2025)
=0/132.8245*132.8245
=0.000

Current CPI (May. 2025) = 132.8245.

Diamyd Medical AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201508 0.004 99.829 0.005
201511 0.007 100.129 0.009
201602 0.011 100.253 0.015
201605 0.004 100.914 0.005
201608 0.005 100.968 0.007
201611 0.014 101.517 0.018
201702 0.001 102.037 0.001
201705 0.004 102.679 0.005
201708 0.006 103.138 0.008
201711 0.010 103.413 0.013
201802 0.000 103.678 0.000
201805 0.001 104.632 0.001
201808 0.002 105.197 0.003
201811 0.005 105.443 0.006
201902 0.001 105.641 0.001
201905 0.014 106.895 0.017
201908 0.003 106.716 0.004
201911 0.002 107.345 0.002
202002 0.001 106.742 0.001
202005 0.001 106.882 0.001
202008 0.001 107.571 0.001
202011 0.001 107.549 0.001
202102 0.000 108.190 0.000
202105 0.002 108.838 0.002
202108 0.001 109.780 0.001
202111 0.000 111.069 0.000
202202 0.003 112.834 0.004
202205 0.005 116.746 0.006
202208 0.001 120.573 0.001
202211 0.003 123.803 0.003
202302 0.001 126.321 0.001
202305 0.002 128.034 0.002
202308 0.001 129.560 0.001
202311 0.000 130.958 0.000
202402 0.000 132.046 0.000
202405 0.001 132.818 0.001
202408 0.000 132.052 0.000
202411 0.000 133.000 0.000
202502 0.001 133.744 0.001
202505 0.000 132.825 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diamyd Medical AB  (OSTO:DMYD B) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Diamyd Medical AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines